The present study examined the pharmacokinetics of anticancer drugs in the cerebrospinal fluid (CSF) during CSF perfusion or injection chemotherapy. A 69-year-old Japanese woman with disseminated glioblastoma received one course of both ventricular-lumbar (V-L) and lumbarventricular (L-V) CSF perfusion chemotherapy, and one course of both ventricular and lumbar injection chemotherapy with methotrexate (MTX), cytosine arabinoside (Ara-C), and nimustine (ACNU). Samples of CSF from the ventricles and lumbar spinal canal were obtained via the Ommaya reservoirs. The drug concentrations in the CSF were measured by either fluorescence polarization immunoassay or high performance liquid chromatography. In the V-L CSF perfusion chemotherapy, the maximum CSF concentrations of the three drugs in the lumbar spinal canal were lower than those in the ventricles. However, the concentrations of MTX and Ara-C in the lumbar spinal canal exceeded those in the ventricles 3 hours after the perfusion. The area under the CSF concentration versus the time curves (AUC) of MTX and Ara-C in the lumbar spinal canal were 175.7 and 76.2%, respectively, of those in the ventricles. In the L-V CSF perfusion chemotherapy, the CSF concentrations of the three drugs in the lumbar spinal canal were higher than those in the ventricle. The AUCs of MTX and Ara-C in the ventricles were 15.5 and 18.4 %, respectively, of those in the lumbar spinal canal. In the ventricular CSF injection, the initial CSF concentrations of the three drugs in the ventricles were higher than those in the lumbar spinal canal. However, the CSF concentrations of MTX and Ara-C in the lumbar spinal canal exceeded those in the ventricles 12 hours after the injection. Although the concentration of ACNU in the ventricles was only detectable at 3 hours after the injection, no concentration in the lumbar spinal canal was detectable. The AUCs of MTX and Ara-C in the lumbar spinal canal were 84.6 and 29.1%, respectively, of those in the ventricles. In the lumbar CSF injection, the CSF concentrations of MTX and Ara-C in the ventricles were detectable but lower than those in the lumbar. Although the CSF concentration of ACNU in the lumbar spinal canal was only detectable at 3 hours after the injection, no concentration in the ventricles was detectable. The AUC of MTX in the ventricles was 0.31% of that in the lumbar spinal canal. These results indicate that CSF perfusion chemotherapy may thus be a more useful treatment than CSF injection chemotherapy to patients with disseminated brain tumors.
Introduction
ACNU decreased with a monoexponential decay pattern (Fig. 1) . The AUCs of MTX and Ara-C in the lumbar spinal canal were 175.7 and 76.2%, respectively, of those in the ventricles. (Table 1 ).
In the L-V CSF perfusion chemotherapy, the maximum CSF concentrations of the three drugs in both the ventricles and the lumbar spinal canal occurred at the end of the perfusion, with 18.3pg/ The CSF concentrations of MTX and Ara-C in the ventricles were detectable but lower than those in the lumbar spinal canal. The CSF concentrations of MTX and Ara-C in the lumbar spinal canal, and that of MTX in the ventricles, decreased with a monoexponential decay pattern. Although the CSF concentration of ACNU in the lumbar spinal canal was detectable only at 3 hours after the injection, that in the ventricles was undetectable (Fig. 4 ) . The AUC of MTX in the ventricles was 0.31% of that in the lumbar spinal canal ( Table 1 ). The CSF AUCs of ACNU in all treatments and that of Ara-C in the ventricles during lumbar CSF injection could not be estimated due to a lack of measurement points.
Discussion
In the present study, we compared the pharmacokinetics of MTX, Ara-C, and ACNU in both ventricular and lumbar CSF in a patient with disseminated glioblastoma during CSF perfusion chemotherapy by both the L-V and V-L routes, and CSF injection chemotherapy via the ventricles and lumbar spinal canal. Meningeal carcinomatosis is generally treated by intrathecal chemotherapy with MTX alone or in combination with Ara-C. However Bleyer12) and Shapiro et al." have reported that when MTX is administered by lumbar puncture, the concentration of MTX that arrives at the subarachnoid space is low. In addition, Rieselbach et al.") have proposed that lumbar injections of MTX and Ara-C do not sufficiently distribute these drugs in the subarachnoid space of the brain. Similar assumptions have been made about anticancer drugs injected through an Ommaya reservoir. We previously showed that high concentrations of MTX, Ara-C, and ACNU arrive at the lumbar spinal canal during V-L perfusion for 2 hours9). In the present study, when the anticancer drugs were perfused by the V-L route, the CSF concentrations of the three drugs in the lumbar spinal canal were initially lower than those in the ventricles, but were higher at 3 hours after perfu- sion. Furthermore, high concentrations of MTX and Ara-C arrived at the ventricles even via the L-V perfusion route. However, the CSF AUC of MTX in the lumbar, spinal canal was higher than that in the ventricles regardless of the perfusion route. These results demonstrate the efficiency of CSF perfusion chemotherapy in distribution of large quantities of anticancer drugs in CSF within a short period of time, allowing for an effective drug concentration to be maintained in the CSF for an extended period of time. However, in contrast to MTX and Ara-C, ACNU was not as effectively distributed. When ACNU was administered by both L-V and V-L perfusion CSF chemotherapy, ACNU was initially detectable in the CSF of both the ventricles and the lumbar spinal canal at the end of perfusion, but was not detectable at 8 hours after the end of perfusion, most likely because the half-life of ACNU is very short (less than 0.4 hours). Furthermore, even at the injection site, the CSF concentration of ACNU decreased to less than 1 gg/mL at 3 hours after the end of perfusion. In an experiment involving the intraventricular injection of ACNU in dogs, Levin et al. reported that a significant amount of ACNU in the CSF is 'hydrolytically degraded before reaching subarachnoid regions distal to the injection site). In our patient, similar results were obtained with respect to the decomposition of ACNU.
Nakagawa et al.8) reported that 9 of 13 patients with meningeal carcinomatosis treated. with V-L perfusion of MTX and Ara-C showed a positive response. In their treatment regimes, MTX (10 to 30 mg)-and Ara-C (40 mg) were infused at 8 to 12 hour intervals on six or nine occasions via an Ornmaya reservoir placed in the lateral ventricle, which was found to be effective in improving cerebral, cranial nerve, and spinal' root signs and symptoms: However, they also found that the drugs displayed unacceptably high levels of toxicity when compared with that of standard intrathecal chemotherapy, indicating that this therapy needs to be investigated further to establish optimal drug doses and repetitive perfusate volumes. We previously reported that the half-lives of MTX, Ara-C, and ACNU during V-L perfusion chemotherapy are about 4,1, and 2 hours, respectively, and consequently, a 3 day interval between CSF perfusion chemotherapy with MTX and Ara-C appears prudent9). The present patient experienced no serious complications as the interval between each CSF perfusion chemotherapy treatment was at least one week. In addition, the side effects of the anticancer drugs in the whole body were negligible, most likely because the transport of these drugs from the CSF to the rest of the body is slight, as previously reported9).
In the present study, a 2 hour perfusion period was used for all treatments, however the drugs, in particular ACNU, underwent decomposition dependent on the perfusion period9). We previously reported that the maximum concentration of ACNU in the lumbar discharged CSF degrades to less than 1% of the concentration in the original perfusion solution after 3 hours of V-L perfusion, due to the extremely short half-life of ACNU that took into account the rapid degradation of ACNU in solution under body temperature). These results of the present study indicate that CSF perfusion chemotherapy with anticancer drugs including Ara-C should be performed within 2 hours, and that these anticancer drugs should be immediately perfused after dissolution in artificial CSF.
In conclusion, CSF perfusion chemotherapy may be a more useful treatment than CSF injection chemotherapy in patients with disseminated brain tumors. However, CSF perfusion chemotherapy is not appropriate for patients with large metastatic deposits and obliteration of the cerebrospinal chamber. Anticancer drugs with extremely short half-life, such as ACNU, that are injected by the lumbar spinal canal route are not efficiently delivered in the whole spinal canal. Except for disseminated tumors in the lumbar spinal canal, lumbar injection chemotherapy may be not a feasible route of treatment. However, future studies on the appropriate concentrations of perfused anticancer drugs, and the possible synergistic effects of drug combinations are required.
